{
    "clinical_study": {
        "@rank": "25079", 
        "arm_group": [
            {
                "arm_group_label": "Under Treatment", 
                "description": "Patients with locally advanced breast cancer, defined as being clinically appropriate for neoadjuvant therapy"
            }, 
            {
                "arm_group_label": "Normal Cohort", 
                "description": "Healthy female volunteers with breast size and epithelial integrity adequate to allow NIR imaging exams"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether an experimental alternative imaging\n      method, Near Infrared Spectroscopy (abbreviated as NIR), can be used with a controlled\n      respiratory system to examine the breasts for cancer. The NIR system uses light beams to\n      produce an image or picture of the inside of the breast. The respiratory system will help\n      researchers get more information about the breast tissue by changing the amount of oxygen\n      the tissue receives during NIR imaging."
        }, 
        "brief_title": "NIR Hypoxia Imaging of Breast Tumor Response to Neoadjuvant Chemotherapy in Vivo", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Anoxia"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  NORMAL cohort\n\n               1. Breast size and epithelial integrity adequate to allow NIR imaging exams\n\n               2. No serious associated psychiatric illnesses\n\n               3. Female, \u226525 and <76 years old\n\n               4. Written informed consent\n\n          -  UNDER TREATMENT cohort\n\n               1. Locally advanced breast cancer, with or without metastatic disease, defined as\n                  being clinically appropriate for neoadjuvant therapy\n\n               2. Breast size and epithelial integrity adequate to allow NIR imaging exams\n\n               3. No serious associated psychiatric illnesses\n\n               4. Female, \u226525 and <76 years old\n\n               5. Written informed consent\n\n        Exclusion Criteria:\n\n          -  both cohorts\n\n               1. Pre-existing respiratory conditions:\n\n                    1. severe chronic obstructive pulmonary disease (including chronic bronchitis\n                       and/or emphysema)\n\n                    2. Other respiratory or lung conditions which would place the patient at risk\n\n                    3. presence of any other significant cardiac or pulmonary symptoms, such as\n                       moderate or severe dyspnea on exertion, orthopnea, or paroxysmal nocturnal\n                       dyspnea\n\n               2. Congestive heart failure\n\n               3. Intolerance of hyperoxia or hypercarbia as delivered by the RespirAct breathing\n                  circuit\n\n               4. Pregnancy"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "76 Years", 
            "minimum_age": "25 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Females with locally advanced breast cancer defined as being clinically appropriate for\n        neoadjuvant therapy and healthy volunteers"
            }
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01934114", 
            "org_study_id": "D1025"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 29, 2013", 
        "location": {
            "contact": {
                "email": "cancer.research.nurse@dartmouth.edu", 
                "last_name": "Peter A Kaufman, MD", 
                "phone": "800-639-6918"
            }, 
            "facility": {
                "address": {
                    "city": "Lebanon", 
                    "country": "United States", 
                    "state": "New Hampshire", 
                    "zip": "03756"
                }, 
                "name": "Dartmouth-Hitchcock Medical Center"
            }, 
            "investigator": {
                "last_name": "Peter A Kaufman, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "NIR (Near Infrared Spectral Tomography)Hypoxia Imaging of Breast Tumor Response to Neoadjuvant Chemotherapy in Vivo.", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Analyze captured data from use of dynamic NIR topographic oximetry (in a cohort of women receiving conventional anthracycline/taxane based adjuvant chemotherapy).Quantify pathological and clinical outcomes.", 
            "measure": "Quantify tumor oxygenation response in patients imaged.Determine capability of imaging dynamic to capture oxygenation changes within the tumor.", 
            "safety_issue": "No", 
            "time_frame": "18 weeks approximately"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01934114"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Dartmouth-Hitchcock Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dartmouth-Hitchcock Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2010", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "August 2013"
    }
}